MRTX849

CAS No. 2326521-71-3

MRTX849( —— )

Catalog No. M21642 CAS No. 2326521-71-3

MRTX849 is a potent selective and covalent KRASG12C inhibitor with potential antineoplastic activity.selectively modifies mutant cysteine 12 in GDP-bound KRASG12C and inhibits KRAS-dependent signaling.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 85 In Stock
25MG 186 In Stock
50MG 332 In Stock
100MG 498 In Stock
500MG 896 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    MRTX849
  • Note
    Research use only, not for human use.
  • Brief Description
    MRTX849 is a potent selective and covalent KRASG12C inhibitor with potential antineoplastic activity.selectively modifies mutant cysteine 12 in GDP-bound KRASG12C and inhibits KRAS-dependent signaling.
  • Description
    MRTX849 is a potent selective and covalent KRASG12C inhibitor with potential antineoplastic activity.selectively modifies mutant cysteine 12 in GDP-bound KRASG12C and inhibits KRAS-dependent signaling.
  • In Vitro
    Cell Viability Assay Cell Line:MIA PaCa-2, H1373, H358, H2122, SW1573, H2030, KYSE-410 cells (G12C); H1299 (WT); A549 (G12S), HCT116 (G13D) cellsConcentration:0.1, 1, 10, 100, 1000, 10000 nM Incubation Time:24 hours Result:Inhibits cell growth in the vast majority of KRAS G12C-mutant cell lines with IC50 values ranging between 10 and 973 nM in the 2D format and between 0.2 and 1042 nM in the 3D format.Western Blot AnalysisCell Line:MIA PaCa-2 cells Concentration:0.24, 0.5, 1.0, 2.0, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000 nM Incubation Time:24 hours Result:Inhibits KRAS-dependent signaling targets including ERK1/2 phosphorylation (Thr202/Tyr204 ERK1; pERK), S6 phosphorylation (RSK-dependent Ser235/236; pS6) and expression of the ERK-regulated DUSP6, each with IC50s in the single-digit nanomolar range in cell lines.
  • In Vivo
    Animal Model:MIA PaCa-2 model (6-8-week-old, female, athymic nude-Foxn1 nu mice)Dosage:1, 3, 10, 30 and 100 mg/kg Administration:Oral gavage; daily until Day 16Result:Rapid tumor regression was observed at the earliest posttreatment tumor measurement and animals in the 30 and 100 mg/kg cohorts exhibited evidence of a complete response at study Day 15. Dosing was stopped at study Day 16 and all 4 mice in the 100 mg/kg cohort and 2 out of 7 mice in the 30 mg/kg cohort remained tumor-free through study Day 70.
  • Synonyms
    ——
  • Pathway
    MAPK/ERK Signaling
  • Target
    Ras
  • Recptor
    KRAS G12C
  • Research Area
    cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    2326521-71-3
  • Formula Weight
    604.12
  • Molecular Formula
    C32H35ClFN7O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (165.53 mM; Need ultrasonic)
  • SMILES
    CN1CCC[C@H]1COc1nc2CN(CCc2c(n1)N1CCN([C@@H](CC#N)C1)C(=O)C(F)=C)c1cccc2cccc(Cl)c12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Jill Hallin Lars D Engstrom Lauren Hargis.The KRAS G12C Inhibitor MRTX849 Provides Insight Toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Cancer Discov. 2020 Jan;10(1):54-71.
molnova catalog
related products
  • Antineoplaston A10

    Antineoplaston A10 is a naturally occurring substance and the first antineoplaston in the human body to be chemically identified. It displayed anti-proliferative action inhibiting cell growth.

  • XRP44X

    XRP44X is a potent inhibitor of Ras-Net (Elk-3) pathway.

  • ARS-1620

    ARS-1620 is a potent, specific and covalent KRAS G12C inhibitor.